Press Release

Editas Medicine to Participate in Upcoming Investor Conferences

February 8, 2018 at 4:01 PM EST

CAMBRIDGE, Mass., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in two upcoming investor conferences. Details are as follows:

BIO CEO & Investor Conference
Date:   Monday, February 12, 2018
Forum:   Presentation
Time:   1:30 p.m. ET
Location:   New York
SunTrust Robinson Humphrey 4th Annual Orphan Drug Day
Date:   Tuesday, February 13, 2018
Forum:   1x1 Meetings
Location:   New York

A live webcast of the presentation will be available on the Investors & Media section of the Editas Medicine website at An archived replay will be available for approximately 30 days following the presentation.

About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit


Cristi Barnett
(617) 401-0113

Mark Mullikin
(617) 401-9083


Primary Logo


Source: Editas Medicine, Inc.